This concise video highlights new findings from the MAPLE-HCM trial in patients with obstructive hypertrophic cardiomyopathy (oHCM). Aficamten achieved its primary endpoint versus metoprolol and demonstrated a favorable safety and tolerability profile. Dr. Garcia provides context for these data and insights on what they may signal for the evolving landscape in cardiac myosin inhibition and oHCM.
advertisement
MAPLE-HCM Results: Favorable Safety and Efficacy for Aficamten in oHCM
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Provider
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
This activity is supported by an independent educational grant from Cytokinetics.
Recommended
Details
Presenters
Overview
This concise video highlights new findings from the MAPLE-HCM trial in patients with obstructive hypertrophic cardiomyopathy (oHCM). Aficamten achieved its primary endpoint versus metoprolol and demonstrated a favorable safety and tolerability profile. Dr. Garcia provides context for these data and insights on what they may signal for the evolving landscape in cardiac myosin inhibition and oHCM.
Provider
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
This activity is supported by an independent educational grant from Cytokinetics.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?